Chinese biopharmaceutical company Shanghai Junshi Biosciences Co. has filed for a US$414 million initial public offering in Hong Kong, according to a security filing released today.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!Register Now
Already have an account or paid subscription?